Citations

Clear

421 citation(s) found for "Short, C".

Quality of life and healthcare resource utilization among adult patients with short bowel syndrome: A mixed‐methods study leveraging an integrated database
Kuk, Deborah , Gower, Megan, Kirby, Michelle, Terreri, Brian , Feldman, Josh , Mundi, Manpreet S. , Feldman, Josh , Mundi, Manpreet S , Chen, Brian , McCue, Maggie

Mayo Clinic

Nutrition in Clinical Practice | November 11, 2025 | Volume: 41 | Issue: 4 | Pages: 1096-1105

10.1002/ncp.70059 | PMID 41215658 Get It

Abstract Background Short bowel syndrome (SBS) is a chronic condition requiring parenteral nutrition (PN) support and multidisciplinary management. However, disparities in access to care and standardized treatment pathways, in addition to economic burden, remain considerable for patients. Understanding healthcare resource utilization (HCRU) and treatment patterns, especially in relation to patient‐reported outcomes (PROs), is critical for improving care. Methods A cross‐sectional, multiphase study was conducted in 2023. This analysis focuses on phase 3, using a deidentified database that integrated claims and PROs from 68 patients in phase 2. Twenty‐three patients were included in the analytic cohort after applying additional criteria. Descriptive statistics summarized patient demographics, HCRU, and treatment patterns for the overall cohort and stratified by median SBS–quality of life (QoL) score. Results The median age at SBS diagnosis was 35 years, and 91% of patients were female. Patients saw a median of 35 different healthcare providers and underwent approximately five procedures before diagnosis. In the 6 months after diagnosis, 39% had been hospitalized, and 26% had emergency room (ER) visits. Healthcare costs increased after diagnosis, with long‐term PN use accounting for 34% of total costs. Patients with worse QoL had a higher number of ER visits than patients with better QoL. Patients who self‐reported being treated by SBS specialists had lower healthcare costs than patients who did not receive specialized care. Conclusion SBS is associated with high HCRU and costs, particularly for patients with poor QoL. Multidisciplinary care, especially from SBS specialists, may help reduce healthcare costs and improve patient outcomes.
Short-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury
Rajani, Ravi R. , Velez, Fulton , Knight, Tyler, Kauffman, Laura, Pascarella, Luigi , Malone, Daniel C. , Niklason, Laura E. , Parikh, Shamik , Velez, Fulton F , Parikh, Shamik , Rasmussen, Todd E.

Mayo Clinic

Trauma Surgery & Acute Care Open | October 29, 2025 | Volume: 10 | Issue: 4 | Pages: e001814

10.1136/tsaco-2025-001814 | PMID 41180255 Get It

Background To evaluate the short-term clinical performance of Symvess (acellular tissue engineered vessel-tyod), formerly known as human acellular vessel, or HAV, compared with autologous vein for the treatment of extremity arterial injury. Methods Subjects treated with acellular tissue engineered vessel (ATEV) from two clinical trials were propensity score-matched on a 1:2 basis to PROspective Observational Vascular Injury Trial (PROOVIT) registry subjects with the same injured artery and treated with autologous vein. Matching characteristics included age, sex, trauma type (penetrating vs blunt), injury severity score, mangled extremity severity score, concomitant fracture, shunt use, and ischemia duration>6 hours. Incidence of outcomes (primary/secondary patency, amputation, conduit infection, reintervention for thrombosis/stenosis, pseudoaneurysm, and death) was assessed by a generalized linear model. Outcomes were assessed at Day 30 (ATEV group) or during initial hospitalization (autologous group). Results ATEV subjects lacking suitable autologous vein (n=67) and PROOVIT subjects treated with autologous vein (n=134) suffered injuries to axillary, brachial, femoral, popliteal, and posterior tibial arteries. Subgroups were clinically similar; Injury Severity Score, Mangled Extremity Severity Score, and duration of follow-up (16 vs 30 days) were higher for the ATEV subgroup. Primary patency for the ATEV versus autologous group was 86.6% versus 91.8%, secondary patency: 91.0% versus 97.7%; amputation: 7.5% versus 8.2%; conduit infection: 1.5% versus 0%; reintervention for thrombosis or stenosis: 6.0% versus 8.2%; and death 4.5% versus 4.5%, respectively. No cases of pseudoaneurysm, true aneurysm, or significant differences between the ATEV and autologous groups for any outcome were observed. Conclusions Short-term outcomes were similar between ATEV subjects without feasible autologous vein, and propensity score-matched autologous vein recipients from the PROOVIT registry. The ATEV may provide effective and safe revascularization in subjects with extremity arterial injury without feasible autologous vein. Level of evidence Level 3, Therapeutic/Care Management
Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial
Rodés‐Cabau, Josep , Nombela‐Franco, Luis , Cruz‐González, Ignacio , Hibbert, Benjamin , Freixa, Xavier , Masson, Jean‐Bernard , Ibrahim, Réda , Estévez‐Loureiro, Rodrigo , Millán, Xavier , Kass, Malek , Champagne, Jean , Laffond, Ana Elvira , Abdel‐Razek, Omar , Labinaz, Marino , Arzamendi, Dabit , Vidal-Calés, Pablo , Pavesi, Marco , Côté, Mélanie, O’Hara, Gilles , Paradis, Jean-Michel , Champagne, Jean , Salinas, Pablo , Laffond, Ana , Abdel-Razek, Omar , Cepas-Guillen, Pedro , Arzamendi, Dabit , Vidal-Cales, Pablo , O'Hara, Gilles , Nombela-Franco, Luis , Hibbert, Benjamin , Cepas‐Guillén, Pedro , Salaün, Erwan

Mayo Clinic

Circulation | October 26, 2025 | Volume: 152 | Issue: 25 | Pages: 1759-1768

10.1161/circulationaha.125.077469 | PMID 41139402 Get It

BACKGROUND: The optimal antithrombotic treatment after transcatheter left atrial appendage closure (LAAC) remains to be determined. The objective of this trial was to compare anticoagulation and antiplatelet therapy for preventing device-related thrombosis (DRT) after LAAC. METHODS: This was a prospective multicenter international randomized trial comparing 2 different antithrombotic strategies for preventing DRT after LAAC in patients with nonvalvular atrial fibrillation. Patients were randomized (1:1) to receive direct oral anticoagulants (DOACs) or dual antiplatelet therapy (DAPT; aspirin+clopidogrel) for 60 days. Patients underwent transesophageal echocardiography at 60 days, and the images were analyzed in a central echocardiography laboratory by experienced echocardiographers blinded to the allocated treatment. The primary outcome was DRT as determined by transesophageal echocardiography 60 days after LAAC in patients receiving the allocated treatment at the time of transesophageal echocardiography (per-protocol analysis). The safety outcome included all-cause mortality, stroke, bleeding, or site-reported DRT within 60 days after LAAC in all randomized patients (intention-to-treat analysis). RESULTS: A total of 510 patients (mean age 77±9 years, 35% women) were included between October 2018 and May 2025, and 253 and 257 patients were randomized to the DOAC and DAPT groups, respectively. Of these, 399 patients underwent transesophageal echocardiography and were receiving the allocated treatment at 60 days after LAAC. The primary outcome occurred in 3 patients (1.5%) in the DOAC group compared with 8 patients (4.1%) in the DAPT group (difference, −2.7% [95% CI, −6.0% to 0.6%]; P =0.110). The safety outcome occurred in 52 patients (22.5%) in the DOAC group compared with 82 patients (34.9%) in the DAPT group (difference, −12.4% [95% CI, −20.6% to −4.2%]; P =0.003), and differences were mainly driven by a lower rate of bleeding events in the DOAC group (44 patients [17.4%] versus 64 patients [24.9%]; difference, −7.5% [95% CI, −14.6% to −0.4%]; P =0.038). CONCLUSIONS: The use of DOACs after LAAC failed to reduce DRT compared with DAPT, but it was associated with an improved safety profile. The results of this study should be interpreted with caution because of statistical power issues related to the narrower-than-expected between-group differences and will need confirmation in future larger studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03568890.
Abstract TH163: Persistence of Blood Pressure Reduction Following Renal Denervation Across Short, Medium, and Long Term Follow-Up
Rezasoltani, Mahsa , Namin, Sara Montazeri , Eshraghi, Reza , Bahrami, Ashkan , noroozi, matin, Akbari, Touba, Behbudi, Fatemeh, Mandegar, Mohammad Hossein , Yazdani, Mohammad Sepehr, Pirdehghan, Reza , Shahid, Farhan , Ebrahimi, Pouya , Namazi, Mohammad Javad , Moradi, Ali, noroozi, matin, Akbari, Touba, Yazdani, Mohammad Sepehr, Ahmed, Raheel

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.th163 Get It

Introduction: Resistant and uncontrolled hypertension pose persistent clinical and public health challenges. Renal denervation, a catheter-based procedure targeting renal sympathetic nerves, has emerged as a promising approach to lower blood pressure by reducing sympathetic overactivity. Hypothesis: A systematic review and meta-analysis of sham-controlled trials investigated whether renal denervation results in sustained blood pressure reduction across short-, medium-, and long-term follow-up. Methods: We searched PubMed, Embase, CENTRAL, and Web of Science through March 2025. The protocol was registered in PROSPERO (CRD420251015937). Randomized, sham-controlled trials of renal denervation in resistant/uncontrolled hypertension were included. Primary outcomes were ambulatory blood pressure (daytime, nighttime, and 24-hour); secondary outcomes included office and home blood pressure measurements. Follow-up durations were categorized into three groups: less than 6 months, 6–12 months, and greater than 12 months. Risk of bias was assessed using RoB-2. Results: Twenty trials (25 reports) with 2,167 RDN patients and 1,744 sham controls were included. Most trials had a low risk of bias. RDN significantly reduced 24-hour SBP (–3.29 mmHg, 95% CI: –5.91 to –0.67) and DBP (–1.42 mmHg, 95% CI: –2.29 to –0.55), despite high heterogeneity (I2 > 90%). Daytime DBP showed a significant reduction (–2.90 mmHg, 95% CI: –4.39 to –1.41), while other BP measures were less consistent. Home SBP was significantly reduced (–5.04 mmHg, 95% CI: –8.50 to –1.58). At 6–12 months, 24-hour SBP reduction persisted (–3.36 mmHg, 95% CI: –5.71 to –1.01), but DBP effects were nonsignificant. Long-term follow-up revealed nonsignificant changes in systolic blood pressure and diastolic blood pressure. Conclusions: Renal denervation modestly lowers BP in the short term (<6 months). Mid-term SBP reduction persists, but diastolic and long-term effects are inconsistent. These findings highlight the need for refined patient selection, optimized techniques, and longer follow-up trials.
Short‐Term Outcomes Following Transurethral Dorsal Buccal Graft Urethroplasty for Female Urethral Strictures
Jefferson, Francis A. , Lee, Yeonsoo Sara , Rafetto, Anessa , Balzano, Felicia, Cohen, Tal , Linder, Brian J. , Warner, J, Rafetto, Anessa N , Sara Lee, Yeonsoo , Linder, Brian J

Mayo Clinic

Neurourology and Urodynamics | October 16, 2025 | Volume: 45 | Issue: 1 | Pages: 155-161

10.1002/nau.70161 | PMID 41097847 Get It

ABSTRACT Introduction and Objectives Female urethral strictures remain a challenging clinical entity with limited data on optimal reconstructive techniques. This study presents 12‐month clinical and patient‐reported outcomes following a novel transurethral approach to dorsal inlay buccal graft urethroplasty. Methods We evaluate the outcomes of consecutive female patients with urethral strictures treated via dorsal inlay buccal graft urethroplasty from October 2021 to November 2024. Preoperative evaluation included cystoscopy, uroflowmetry, and/or voiding cystourethrogram. Follow‐up at 4 and 12 months included cystoscopy, uroflowmetry, and patient‐reported outcomes measured via the Global Response Assessment. Success was defined as absence of recurrence on cystourethroscopy. Results Twenty‐one patients were included in the study, with 95% having undergone prior treatments (90% dilation/DVIU and 9% urethroplasty). Stricture locations varied across the distal (33%), mid (19%), proximal (19%), and multifocal/pan urethral (19%). The median operative duration was 60 min (IQR: 56–86) and all were discharged on the day of surgery. Nineteen patients (90%) underwent a dorsal inlay procedure, while two (10%) required combined dorsal and ventral inlay due to obliterative stricture. No complications were observed. The median follow‐up was 13.2 (IQR: 5.1–23.5) months, during which time 1 patient underwent retreatment for recurrent stricture. Clinical success was 95% at 4 months and 92% at 12 months. Median peak urinary flow rate preoperatively versus 4‐month postoperatively was 7.0 cc/s versus 13.0 cc/s ( p = 0.20) and at 12‐month postoperatively was 13.3 cc/s ( p = 0.50). 90% of patients reported improvement on the Global Response Assessment. There were no cases of de novo stress urinary incontinence. Conclusions This novel transurethral dorsal inlay buccal graft urethroplasty offers a safe and efficient treatment for female urethral strictures with durable clinical and patient‐reported outcomes at 12 months. The technique's minimal urethral mobilization translates into shorter operative times and a low risk of stress incontinence, making it a promising alternative to traditional approaches.
Rare but Relevant? Assessing Variants in Dystonia‐Linked Genes in Parkinson's Disease
Screven, Laurel A. , Tan, Ai Huey , Fenn, Matilda, Frost, Joshua L.I., Jankovic, Joseph, Jasaityte, Simona , Jeon, Beomseok , Sarmiento, Ignacio Juan Keller , Krüger, Rejko , Kuhlenbäumer, Gregor , Schirinzi, Tommaso , Shulman, Joshua M., Uitti, Ryan J. , Wu, Lesley , Zeuner, Kirsten E., Blauwendraat, Cornelis , Singleton, Andrew, Lohmann, Katja , (GP2), the Global Parkinson's Genetics Program, Tan, Ai Huey , Jeon, Beom Seok , Lin, Chin-Hsien , Schirinzi, Tommaso , Shin, Jung Hwan , Tay, Yi Wen , Uitti, Ryan, Warner, Thomas T. , Wszolek, Z.K. , Wu, Ruey-Meei , Blauwendraat, Cornelis , Morris, Huw R , Lohmann, Katja , Lange, Lara Mariah , Fang, Zih‐Hua , Alcalay, Roy N. , Amouri, Rim , Bovenzi, Roberta , Frost, Joshua L.I., Jankovic, Joseph J. , Jaunmuktane, Zane , Lin, Chin‐Hsien , Pavelka, Lukas , Periñán, María Teresa , Sassi, Samia Ben , Shulman, Joshua M. , Wszołek, Zbigniew K. , Wu, Ruey‐Meei , Singleton, Andrew , Mencacci, Niccolò Emanuele , Morris, Huw R. , Lim, Shen‐Yang , Klein, Christine , (GP2), the Global Parkinson's Genetics Program

Mayo Clinic

Movement Disorders | October 11, 2025 | Volume: 41 | Issue: 1 | Pages: 247-259

10.1002/mds.70073 | PMID 41074695 Get It

Abstract Background Dystonia and Parkinson's disease (PD) exhibit clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective The aim was to assess the frequency of dystonia‐linked pathogenic variants in PD. Methods We screened sequencing data from 15,684 individuals (8272 PD, 3200 atypical parkinsonism, and 4212 unaffected) from the Global Parkinson's Genetics Program (GP2) and Accelerating Medicines Partnership‐Parkinson's Disease (AMP‐PD) for variants in genes linked to isolated dystonia, dystonia‐parkinsonism, and myoclonus‐dystonia. Results Pathogenic variants were identified only in PD patients. Forty‐five PD individuals (0.54%) carried 26 distinct (likely) pathogenic variants in nine dystonia‐linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion Though rare, pathogenic variants in dystonia‐linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD‐relevant gene with clinical implications, whereas variants identified in other genes are rare and of uncertain relation to the PD phenotype. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Short-course versus long-course antibiotic treatment for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials
Fite, Amsalu, Farooqi, Mashood , Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Samreen Rizwan Ahmed, Sahra, Syeda , Torres, Antoni, Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, Nihar Yogesh, Cheema, Huzaifa Ahmad , Singh, Harpreet , Ahmad, Sharjeel , Ahmad, Faran , Torres, Antoní

Mayo Clinic

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine | September 25, 2025 | Volume: 9 | Issue: 5 | Pages: 247-254

10.1080/24745332.2025.2552193 Get It

Development of a diagnosis and treatment formulary for short-term medical service trips
Flores, Emily , Lefevers, Kacey M, Blair, Janis E. , Flores, Emily K

Mayo Clinic

International Journal of Pharmacy Practice | September 12, 2025 | Volume: 34 | Issue: 4 | Pages: 505-508

10.1093/ijpp/riaf081 | PMID 40985931 Get It

Abstract Objective To create a short-term medical service trip (MST) focused, standardized, evidence-based, cost-effective, locally appropriate formulary. Methods Documents from the World Health Organization (WHO), related entities, and primary literature were reviewed to determine best practices. Specific diagnosis and treatment formularies (DTFs) for MST use in the WHO Regions of Africa and the Americas were created. Key findings The DTF guiding principles were being WHO-region specific, addressing primary health needs, including essential medications based on disease prevalence, local availability and affordability, and optimizing patient labeling. Conclusions A thoughtfully crafted DTF for MSTs is one way to advance equitable and safe health care.
High‐Power Short‐Duration Ablation Versus Conventional Power Ablation in Pulmonary Vein Isolation in Patients With Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Cabral, David C. B. I. , Rivera, André , Braga, Marcelo Antonio Pinheiro , Passos, Bárbara Mariz Ferreira, Ternes, Caique M. P. , Brígido, Alexandra Régia Dantas , Carvalho, Guilherme Dagostin de , Deshmukh, Abhishek , DeSimone, Christopher V. , Ferreira Félix, Iuri, de Carvalho, Guilherme Dagostin , Deshmukh, Abhishek J , DeSimone, Christopher V , Ternes, Caique M P , Félix, Iuri Ferreira , Rivera, A

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 31, 2025 | Volume: 36 | Issue: 10 | Pages: 2620-2628

10.1111/jce.16735 | PMID 40886137 Get It

ABSTRACT Background High‐power short‐duration (HPSD) ablation has emerged as a promising alternative to conventional power delivery (CPD) for pulmonary vein isolation (PVI) among patients with atrial fibrillation (AF), though its efficacy, procedural efficiency, and safety profile remain uncertain. Aims To evaluate and compare the efficacy, procedural efficiency, and safety of HPSD versus CPD ablation strategies for PVI in patients with AF through a systematic review and meta‐analysis of randomized controlled trials (RCTs). Materials and Methods PubMed, Embase, Cochrane Library, and ClinicalTrials.Gov databases were systematically searched for RCTs comparing HPSD with CPD ablation for PVI in patients with AF. Random‐effects models were used to pool hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI). R version 4.4.2 was used for statistical analysis. Results Eight RCTs with 1094 patients (558 undergoing HPSD and 536 undergoing CPD ablation) were included. No significant differences were found in freedom from arrhythmia during the follow‐up period (HR: 0.77; 95% CI: 0.41–1.45; p = 0.424). AF recurrence did not differ (RR: 0.83; 95% CI: 0.59–1.16; p = 0.268) between groups. HPSD had a significantly shorter procedural (mean difference [MD]: −21.93 min; 95% CI: −31.34, −12.53; p < 0.001) and RF ablation times (MD: −13.87 min; 95% CI: −19.46, −8.27; p < 0.001). No differences were observed in fluoroscopy time and first‐pass isolation for right and left pulmonary veins. There was no difference in esophageal lesion rates, pericardial, or neurological complications, but there was a higher incidence of steam pops in HPSD (RR: 3.42; 95% CI: 1.45–8.09; p = 0.005). Discussion Although HPSD ablation did not significantly improve freedom from arrhythmia or reduce AF recurrence compared to CPD, it demonstrated enhanced procedural efficiency, with shorter procedure and RF ablation times. Despite the higher rate of steam pops, the overall safety profile was similar between both groups. Conclusion High‐power short‐duration ablation for pulmonary vein isolation in atrial fibrillation demonstrated comparable efficacy and safety to conventional power delivery, with the added benefit of shorter procedure and RF ablation times. However, HPSD ablation was associated with increased occurrence of steam pops.
AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome
Nimani, Saranda , Bains, Sahej , Alerni, Nicolò , Ördög, Balázs , Horváth, András , Matas, Lluis , Louradour, Julien , Giammarino, Lucilla , Tester, David J. , Beslac, Olgica, López, Rubén , Meier, Stefan , Christoforou, Nicolas , Barbieri, Miriam , Vashanthakumar, Varjany, Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Kim, C.S. John, Zhou, Wei , Ye, Dan , Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Zehender, Manfred, Brunner, Michael, Heijman, Jordi , Casoni, Daniela , Brooks, Gabriel , Odening, Katja E. , Egle, Manuel , Barbieri, Miriam , Christoph, Jan , Brunner, Michael , Heijman, Jordi , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Vashanthakumar, Varjany, Parodi, Chiara, Barry, Michael A. , Praz, Fabien , Ackerman, Michael

Mayo Clinic

European Heart Journal | August 15, 2025 | Volume: 47 | Issue: 2 | Pages: 199-213

10.1093/eurheartj/ehaf660 | PMID 40884219 Get It

Abstract Background and Aims Type 1 short QT syndrome (SQT1) is a genetic channelopathy caused by gain-of-function variants in KCNH2, resulting in shortened cardiac repolarization and QT intervals, which predispose patients to ventricular arrhythmias and sudden cardiac death. This study aimed to investigate the therapeutic efficacy of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. Methods KCNH2-SupRep was developed by combining a KCNH2-shRNA with its corresponding shRNA-immune KCNH2-cDNA into an AAV9 vector, delivered directly into the aortic root (1 × 1010 vg/kg). Therapeutic efficacy was evaluated in vivo by electrocardiogram, ex vivo by optical mapping, and at cellular levels by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs). Results In vivo, KCNH2-SupRep normalized the heart rate-corrected QT interval (QTc) in SQT1 rabbits, without affecting repolarization heterogeneity. Ex vivo, KCNH2-SupRep corrected the action potential duration (APD90) and resolved the increased apicobasal APD90 heterogeneity observed in untreated (UT)-SQT1 hearts, supporting an antiarrhythmic effect, which was further validated by reduced re-entry formation in silico. At cellular levels, KCNH2-SupRep prolonged APD90 in VCMs from SupRep-SQT1 rabbits closer to wildtype levels compared with UT- and sham-SQT1. Additionally, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window and normalized IKr in nearly 50% of VCMs, in line with a 50%–60% suppression of the mutant KCNH2 transcript. Conclusions This proof-of-concept study is the first to demonstrate the efficacy of gene therapy for SQT1 in a medium-sized animal model. KCNH2-SupRep gene therapy successfully corrected the pathologic phenotype in vivo, ex vivo, and at cellular levels in transgenic SQT1 rabbits.